Cargando…
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
BACKGROUND: Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy. METHODS: We conducted a retrospective cohort study of...
Autores principales: | Sussman, Tamara A, Li, Hong, Hobbs, Brian, Funchain, Pauline, McCrae, Keith R, Khorana, Alok A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805375/ https://www.ncbi.nlm.nih.gov/pubmed/33436486 http://dx.doi.org/10.1136/jitc-2020-001719 |
Ejemplares similares
-
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016
por: Sussman, Tamara A, et al.
Publicado: (2022) -
Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer
por: Khorana, Alok A, et al.
Publicado: (2023) -
RNA expression and risk of venous thromboembolism in lung cancer
por: Sussman, Tamara A., et al.
Publicado: (2019) -
Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
por: Sleiman, Joseph, et al.
Publicado: (2021) -
Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)